Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of "Moderate Buy" from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $16.60.

Several brokerages have issued reports on TBPH. BTIG Research lifted their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Wall Street Zen cut shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research report on Tuesday, June 17th.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the sale, the senior vice president owned 336,918 shares of the company's stock, valued at $3,706,098. The trade was a 6.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.90% of the company's stock.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nuveen LLC purchased a new stake in Theravance Biopharma during the first quarter worth about $3,348,000. Newtyn Management LLC increased its stake in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after buying an additional 258,337 shares during the period. Acadian Asset Management LLC increased its stake in shares of Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after buying an additional 174,451 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Theravance Biopharma by 20.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after buying an additional 95,304 shares during the period. Finally, Jane Street Group LLC increased its stake in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after buying an additional 88,540 shares during the period. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Price Performance

Theravance Biopharma stock traded up $0.06 during trading hours on Friday, reaching $11.53. The stock had a trading volume of 164,842 shares, compared to its average volume of 254,812. The stock has a market cap of $576.50 million, a PE ratio of -9.77 and a beta of -0.02. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.82. The company has a fifty day simple moving average of $10.33 and a 200-day simple moving average of $9.61.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. Research analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.